Genscript Biotech Past Earnings Performance
Past criteria checks 0/6
Genscript Biotech's earnings have been declining at an average annual rate of -8.7%, while the Life Sciences industry saw earnings growing at 19.8% annually. Revenues have been growing at an average rate of 26.5% per year.
Key information
-8.7%
Earnings growth rate
-6.4%
EPS growth rate
Life Sciences Industry Growth | 41.4% |
Revenue growth rate | 26.5% |
Return on equity | -17.8% |
Net Margin | -17.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13Revenue & Expenses Breakdown
How Genscript Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1,010 | -177 | 424 | 462 |
31 Mar 24 | 925 | -136 | 408 | 447 |
31 Dec 23 | 840 | -95 | 393 | 433 |
30 Sep 23 | 773 | -140 | 383 | 426 |
30 Jun 23 | 707 | -185 | 374 | 420 |
31 Mar 23 | 667 | -206 | 363 | 405 |
31 Dec 22 | 626 | -227 | 352 | 390 |
30 Sep 22 | 598 | -315 | 354 | 375 |
30 Jun 22 | 570 | -403 | 356 | 361 |
31 Mar 22 | 530 | -381 | 330 | 360 |
31 Dec 21 | 490 | -359 | 303 | 358 |
30 Sep 21 | 483 | -265 | 270 | 341 |
30 Jun 21 | 454 | -183 | 235 | 323 |
31 Mar 21 | 422 | -194 | 216 | 293 |
31 Dec 20 | 391 | -205 | 197 | 263 |
30 Sep 20 | 354 | -194 | 171 | 251 |
30 Jun 20 | 318 | -183 | 146 | 239 |
31 Mar 20 | 296 | -140 | 136 | 212 |
31 Dec 19 | 273 | -97 | 126 | 186 |
30 Sep 19 | 257 | -59 | 112 | 148 |
30 Jun 19 | 241 | -22 | 98 | 109 |
31 Mar 19 | 236 | 0 | 89 | 92 |
31 Dec 18 | 231 | 21 | 79 | 74 |
30 Sep 18 | 216 | 24 | 72 | 58 |
30 Jun 18 | 201 | 27 | 65 | 41 |
31 Mar 18 | 177 | 26 | 56 | 30 |
31 Dec 17 | 153 | 26 | 47 | 18 |
30 Sep 17 | 139 | 27 | 48 | 11 |
30 Jun 17 | 125 | 28 | 49 | 5 |
31 Mar 17 | 120 | 27 | 50 | 2 |
31 Dec 16 | 115 | 26 | 51 | 0 |
30 Sep 16 | 107 | 26 | 50 | 0 |
30 Jun 16 | 99 | 25 | 48 | 0 |
31 Mar 16 | 93 | 21 | 47 | 0 |
31 Dec 15 | 87 | 18 | 46 | 0 |
30 Sep 15 | 82 | 13 | 43 | 0 |
30 Jun 15 | 78 | 8 | 39 | 0 |
31 Mar 15 | 74 | 7 | 38 | 0 |
31 Dec 14 | 70 | 6 | 37 | 0 |
Quality Earnings: 1548 is currently unprofitable.
Growing Profit Margin: 1548 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1548 is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare 1548's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1548 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (1.4%).
Return on Equity
High ROE: 1548 has a negative Return on Equity (-17.82%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/04 05:54 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genscript Biotech Corporation is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Linda Lu | BOCI Research Ltd. |
Jin Zhang | China International Capital Corporation Limited |
Yue-Kwong Lui | China Renaissance Securities |